LONDON–(BUSINESS WIRE)– This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. 23 October 2026 OBERON AIM VCT PLC (the “Company”) Issue of Equity and Total Voting Rights The Company announced on 23 March
Tag: Business Wire
CAMBRIDGE, England–(BUSINESS WIRE)–Mundipharma hat heute zusätzliche Ergebnisse aus der globalen klinischen Phase-III-Studie ReSPECT bekannt gegeben, in der REZZAYO® (Rezafunginacetat) zur Prophylaxe invasiver Pilzerkrankungen (IFD) bei erwachsenen Patienten untersucht wurde, die sich einer allogenen hämatopoetischen Stammzelltransplantation (allo-HSZT) unterziehen. Die Ergebnisse der Phase-III-Studie wurden heute im Rahmen eines Late-Breaking-Vortrags auf der IDWeek 2026 präsentiert. Die Prä
CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–Mundipharma anunció nuevos resultados del ensayo clínico internacional de fase III ReSPECT, que evalúa REZZAYO® (acetato de rezafungina) para prevenir las infecciones fúngicas invasivas (IFI) en adultos sometidos a un trasplante alogénico de células madre hematopoyéticas (alo-TCMH). Los resultados se presentaron en una comunicación oral de última hora durante IDWeek 2026. La presentación amplía la información sobre los principales resultados de ReSPECT, a
CAMBRIDGE, Inghilterra–(BUSINESS WIRE)–Mundipharma oggi ha annunciato ulteriori risultati dello studio clinico globale di fase III ReSPECT, che ha valutato REZZAYO® (rezafungina acetato) per la profilassi delle infezioni fungine invasive in pazienti adulti sottoposti a trapianto allogenico di cellule staminali ematopoietiche (allo-HSCT). I risultati di fase III sono stati presentati oggi in una comunicazione orale “late-breaking” all’IDWeek 2026. La presentazione fornisce ulteriori dettagli d
CAMBRIDGE, Engeland–(BUSINESS WIRE)–Mundipharma heeft vandaag aanvullende resultaten bekendgemaakt van de wereldwijde Fase III ReSPECT-studie, waarin REZZAYO® (rezafungineacetaat) wordt onderzocht voor de profylaxe van invasieve schimmelinfecties (ISI’s) bij volwassen patiënten die een allogene hematopoëtische stamceltransplantatie (allo-HSCT) ondergaan. De bevindingen uit deze Fase III-studie werden vandaag gepresenteerd als een allernieuwste mondeling presentatie tijdens IDWeek 2026. De pre
KYOTO, Japan–(BUSINESS WIRE)–As announced in the press release, “Nidec Discloses the Investigation Report Issued by the Executive Responsibility Investigation Committee,” dated October 20, 2026, Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) hereby discloses an English version of the digest of the Executive Responsibility Investigation Committee’s investigation report as shown in the attachment, as the translation was completed today. Please see the full release here: https://www.release.tdne
ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world’s largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only read
CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–A Mundipharma anunciou hoje resultados adicionais do estudo clínico global de Fase III ReSPECT, que avalia o REZZAYO® (acetato de rezafungina) para a profilaxia de doenças fúngicas invasivas (DFIs) em pacientes adultos submetidos ao transplante alogênico de células-tronco hematopoiéticas (alo-TCTH). Os achados da Fase III foram apresentados hoje em uma sessão oral de última hora no IDWeek 2026. A apresentação traz detalhes adicionais aos resultados prelim
CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–A Mundipharma anunciou hoje resultados adicionais do estudo clínico global de Fase III ReSPECT, que avalia o REZZAYO® (acetato de rezafungina) para a profilaxia de doenças fúngicas invasivas (DFIs) em pacientes adultos submetidos ao transplante alogênico de células-tronco hematopoiéticas (alo-TCTH). Os achados da Fase III foram apresentados hoje em uma sessão oral de última hora no IDWeek 2026. A apresentação traz detalhes adicionais aos resultados prelim
MORRISVILLE, N.C.–(BUSINESS WIRE)–(美國商業資訊)– Lenovo 今日擴充旗下的 Lenovo AI Library，新增多個經驗證的 AI 使用案例，進一步拓展其企業級解決方案組合，協助企業從 AI 實驗階段邁向可衡量的業務成果，速度最多較度身訂造的實施方案快 24 倍1。新增的使用案例現已於 Lenovo AI Library 上線，為企業提供經過驗證的起步點，從而加快 AI 部署並更早實現投資回報。與此同時，The Futurum Group 與 Signal65 進行的最新研究亦驗證了 Lenovo 的 AI Library、基礎設施及服務，如何協助企業隨部署規模擴大而將 AI 經濟效益最佳化，同時提升每個 token 的價值。 Lenovo AI Library 的新增項目，涵蓋具高影響力的企業及行業使用案例，以協助企業提升員工生產力、推動 IT 營運現代化、提升客戶服務質素，並將營運數據轉化為可付諸行動的洞察： Lenovo AI Computer Vision for Retail 將影片及營運數據轉化為洞察，協助零售商縮短客戶等